$ADIL
ADIAL PHARMACEUTICALS, INC.

2024 Q4 Form 10-Q Financial Statement

#000121390024097519 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M
YoY Change 2.59%
% of Gross Profit
Research & Development $1.032M
YoY Change 398.07%
% of Gross Profit
Depreciation & Amortization $140.00
YoY Change
% of Gross Profit
Operating Expenses $2.211M
YoY Change 62.86%
Operating Profit -$2.211M
YoY Change 62.86%
Interest Expense $19.67K
YoY Change 96.7%
% of Operating Profit
Other Income/Expense, Net $19.67K
YoY Change 92.17%
Pretax Income -$2.192M
YoY Change 62.63%
Income Tax
% Of Pretax Income
Net Earnings -$2.192M
YoY Change 58.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.38
Diluted Earnings Per Share -$0.38
COMMON SHARES
Basic Shares Outstanding 6.406M shares 6.403M shares
Diluted Shares Outstanding 5.836M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.204M
YoY Change 1526.36%
Cash & Equivalents $5.204M
Short-Term Investments
Other Short-Term Assets $414.2K
YoY Change -11.86%
Inventory
Prepaid Expenses $4.430K
Receivables
Other Receivables
Total Short-Term Assets $5.619M
YoY Change 394.82%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $3.489K
YoY Change
Long-Term Investments $1.091M
YoY Change -36.88%
Other Assets
YoY Change
Total Long-Term Assets $1.094M
YoY Change -36.83%
TOTAL ASSETS
Total Short-Term Assets $5.619M
Total Long-Term Assets $1.094M
Total Assets $6.713M
YoY Change 134.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $318.1K
YoY Change 288.3%
Accrued Expenses $500.9K
YoY Change 22.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $829.0K
YoY Change 56.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $829.0K
Total Long-Term Liabilities $0.00
Total Liabilities $829.0K
YoY Change 56.96%
SHAREHOLDERS EQUITY
Retained Earnings -$79.92M
YoY Change 19.51%
Common Stock $6.404K
YoY Change 425.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.884M
YoY Change
Total Liabilities & Shareholders Equity $6.713M
YoY Change 134.1%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.192M
YoY Change 58.26%
Depreciation, Depletion And Amortization $140.00
YoY Change
Cash From Operating Activities -$1.694M
YoY Change 21.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.610M
YoY Change 2478.85%
NET CHANGE
Cash From Operating Activities -1.694M
Cash From Investing Activities
Cash From Financing Activities 3.610M
Net Change In Cash 1.916M
YoY Change -312.92%
FREE CASH FLOW
Cash From Operating Activities -$1.694M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
dei Trading Symbol
TradingSymbol
ADIL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38323
dei Entity Registrant Name
EntityRegistrantName
ADIAL PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3074668
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23060
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Address Address Line1
EntityAddressAddressLine1
4870 Sadler Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Glen Allen
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei City Area Code
CityAreaCode
(804)
dei Local Phone Number
LocalPhoneNumber
487-8196
dei Security12b Title
Security12bTitle
Common Stock
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6405781 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5204346 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2827082 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4430 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
409807 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
371597 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
5618583 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3198679 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3489 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3913 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
1090647 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
1534013 usd
CY2024Q3 us-gaap Assets
Assets
6712719 usd
CY2023Q4 us-gaap Assets
Assets
4736605 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
318118 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
103325 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
500928 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
477747 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
829046 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
653076 usd
CY2024Q3 us-gaap Liabilities
Liabilities
829046 usd
CY2023Q4 us-gaap Liabilities
Liabilities
653076 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6405781 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6405781 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1663421 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1663421 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
6404 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1663 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85801802 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
72879738 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79924533 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68797872 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5883673 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4083529 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6712719 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4736605 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1031633 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
207128 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2498433 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1002640 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1179841 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1150808 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3845293 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4101466 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2211474 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1357936 usd
us-gaap Operating Expenses
OperatingExpenses
6343726 usd
us-gaap Operating Expenses
OperatingExpenses
5104106 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2211474 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1357936 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6343726 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5104106 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
50694 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
10236 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
124901 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
58554 usd
adil Inducement Expense
InducementExpense
4464427 usd
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-31023 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-443366 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-51901 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19671 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10236 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4782935 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6653 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2191803 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1347700 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11126661 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5097453 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2191803 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1347700 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11126661 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5097453 usd
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-37276 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1894445 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2191803 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1384976 usd
us-gaap Net Income Loss
NetIncomeLoss
-11126661 usd
us-gaap Net Income Loss
NetIncomeLoss
-3203008 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.38
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.38
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.14
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.14
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.57
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.57
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.54
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.54
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.03
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-0.03
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
1.69
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
1.69
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5835682 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
5835682 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1178537 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1178537 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4330158 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
4330158 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1121328 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1121328 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4083529 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
177003 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
48987 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3824264 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
4464427 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6476560 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6121650 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
153391 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
48987 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
411091 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2458298 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4276821 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
136383 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
51878 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3610394 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2191803 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5883673 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3276494 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
397442 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
62135 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
609613 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2905836 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1439848 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
310263 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
427317 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
51901 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1087804 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3317191 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
293665 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
49526 usd
CY2023Q3 adil Adjustments To Additional Paid In Capital Equitybased Compensation Forfeiture Of Unvested Stock Issuances On Employee Termination
AdjustmentsToAdditionalPaidInCapitalEquitybasedCompensationForfeitureOfUnvestedStockIssuancesOnEmployeeTermination
-74817 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
140330 usd
CY2023Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-1661 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1384976 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2339258 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11126661 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5097453 usd
us-gaap Share Based Compensation
ShareBasedCompensation
616629 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1465531 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
51901 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
424 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
423 usd
adil Inducement Expense
InducementExpense
4464427 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-443366 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1690 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
38210 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
120165 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
4430 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
23181 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-554713 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-37942 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-145000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
214793 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-197232 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-24062 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5468485 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4598398 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-985856 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5468485 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5584254 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1150000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1150000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4021485 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
749943 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3824264 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
58 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1661 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7845749 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
748340 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2377264 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3685914 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2827082 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4001794 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5204346 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
315880 usd
us-gaap Stock Issued1
StockIssued1
1727897 usd
adil Reimbursement Receivable In Connection With Sale Of Purnovate
ReimbursementReceivableInConnectionWithSaleOfPurnovate
737276 usd
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-10-01
CY2024Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3800000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires Company management to make estimates and assumptions that affect the amounts of assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results might differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant items subject to such estimates and assumptions include accruals associated with third party providers supporting clinical trials and income tax asset realization.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4562201 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
559748 shares
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
4500000 usd
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
927000 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1600000 usd
adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
260748 usd
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
455431 usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
716179 usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-716179 usd
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
174 usd
adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
14000 usd
CY2023Q3 adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
-37276 usd
adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
2624798 usd
CY2023Q3 adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
-37276 usd
adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
2610624 usd
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-37276 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1894445 usd
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-37276 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1894445 usd
CY2024Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
283268 usd
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
165926 usd
adil Percentage Of Outstanding Equity
PercentageOfOutstandingEquity
0.1161 pure
CY2024Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
413557 usd
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
421365 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
81555 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
50566 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5816 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5816 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
500928 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
477747 usd
CY2023Q2 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
3000000 usd
CY2023Q2 adil Average Daily Trading Value
AverageDailyTradingValue
2000000 usd
CY2023Q2 adil Volume Weighted Average Price Percentage
VolumeWeightedAveragePricePercentage
0.95 pure
us-gaap Other Expenses
OtherExpenses
51901 usd
adil Fixed Commission Rate
FixedCommissionRate
0.03 pure
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3500000 usd
CY2024Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
3100000 usd
adil Fair Value Per Warrant
FairValuePerWarrant
2.066
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
1.94
us-gaap Deferred Sales Inducements Amortization Expense
DeferredSalesInducementsAmortizationExpense
4464427 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
500000 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1189 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0423 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
205000 shares
adil Share Based Compensation Granted Fair Value
ShareBasedCompensationGrantedFairValue
232812 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.14
adil Weighted Average Remaining Service Period
WeightedAverageRemainingServicePeriod
P3Y
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
463199 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y29D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
188261 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
268374 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
616629 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1465531 usd
adil License Fees And Milestone Payments Description
LicenseFeesAndMilestonePaymentsDescription
More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of a New Drug Application by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense itself. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
us-gaap Royalty Expense
RoyaltyExpense
30000 usd
CY2024Q3 adil License Fees
LicenseFees
20000 usd
us-gaap Royalty Expense
RoyaltyExpense
30000 usd
CY2018Q2 us-gaap Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage
DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
0.05 pure
CY2018Q2 us-gaap Grants Receivable
GrantsReceivable
1000000 usd
CY2018Q2 adil Percentage Of Amount To Be Paid In Cash
PercentageOfAmountToBePaidInCash
0.50 pure
CY2018Q2 adil Percentage Of Amount To Be Paid In Stock
PercentageOfAmountToBePaidInStock
0.50 pure
adil Annual Fee
AnnualFee
375000 usd
CY2022Q3 adil Annual Fee
AnnualFee
430000 usd
CY2024Q2 us-gaap Payments For Fees
PaymentsForFees
56792 usd
CY2022Q4 us-gaap Other Commitment
OtherCommitment
209250 usd
CY2023Q1 us-gaap Deferred Compensation Arrangement With Individual Distribution Paid
DeferredCompensationArrangementWithIndividualDistributionPaid
22000 usd
CY2024Q2 us-gaap Payments For Fees
PaymentsForFees
1437000 usd
adil Other Payments
OtherPayments
1284000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4430 usd
adil Additional Expense
AdditionalExpense
147123 usd
adil Cash Payments
CashPayments
142694 usd
CY2024Q3 us-gaap Other Commitment
OtherCommitment
481000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 adil Inducement Expense
InducementExpense
usd
CY2023Q3 adil Inducement Expense
InducementExpense
usd
adil Inducement Expense
InducementExpense
usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2024Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
CY2024Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
adil Inducement Expense
InducementExpense
usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Stock Issued1
StockIssued1
usd
adil Reimbursement Receivable In Connection With Sale Of Purnovate
ReimbursementReceivableInConnectionWithSaleOfPurnovate
usd
CY2024Q3 adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
usd
CY2023Q3 adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
usd
adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
usd
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
usd
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
usd
CY2024Q3 adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
usd
CY2023Q3 adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
usd
adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
usd
CY2024Q3 adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
usd
adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
usd
CY2024Q3 adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
usd
adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
usd
CY2024Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
usd
CY2024Q3 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
CY2023Q3 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001513525

Files In Submission

Name View Source Status
adil-20240930_cal.xml Edgar Link unprocessable
0001213900-24-097519-index-headers.html Edgar Link pending
0001213900-24-097519-index.html Edgar Link pending
0001213900-24-097519.txt Edgar Link pending
0001213900-24-097519-xbrl.zip Edgar Link pending
adil-20240930.xsd Edgar Link pending
ea0220287-10q_adial.htm Edgar Link pending
ea022028701ex31-1_adial.htm Edgar Link pending
ea022028701ex31-2_adial.htm Edgar Link pending
ea022028701ex32-1_adial.htm Edgar Link pending
ea022028701ex32-2_adial.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
adil-20240930_def.xml Edgar Link unprocessable
adil-20240930_lab.xml Edgar Link unprocessable
adil-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0220287-10q_adial_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending